Please assess the completion status of the following clinical trial:

Trial Title: HD Melphalan and SCT in Patients With IGDD or LCDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed light-chain deposition disease based on the following criteria:~  * Deposition of granular material containing free light-chain (FLC) immunoglobulins that did not bind Congo red~ * Evidence of a plasma cell dyscrasia, as defined by any of the following:~    * Monoclonal gammopathy in the serum or urine by immunofixation electrophoresis~   * Clonal plasmacytosis on bone marrow biopsy by immuno-histochemical~   * Elevated serum levels of FLC~* Patients may enroll after stem cell collection (SCC) if all prestudy requirements are completed prior to starting SCC (i.e., ≥ 2.5 x 10\^6 cells available for transplantation)~PRIOR CONCURRENT THERAPY:~* Prior chemotherapy with alkylating agent allowed provided there is no evidence of myelodysplastic syndromes~* Prior total dose of melphalan \< 300 mg~* More than 4 weeks since prior cytotoxic therapy and recovered~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Left Ventricular Ejection Fraction (LVEF) ≥ 45% within the past 90 days~* diffusing capacity of lung for carbon monoxide (DLCO) ≥ 50%~Exclusion Criteria:~* No overt multiple myeloma, as defined by any of the following:~  * Greater than 30% bone marrow plasmacytosis~ * Extensive (i.e., \> 2) lytic lesions~ * Hypercalcemia~* No myocardial infarction, congestive heart failure, or arrhythmia refractory to therapy within the past 6 months~* No prior malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer from which the patient is currently in complete response, or any other cancer from which the patient has been disease-free for the past 5 years~* No HIV positivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- SCT with melphalan conditioning (Type: EXPERIMENTAL): Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).